PDL BioPharma, Inc. Additional Paid In Capital

Additional Paid In Capital of PDLI for past 10 years: annual, quarterly and twelve month trailing (TTM) including Additional Paid In Capital growth rates and interactive chart.


Highlights and Quick Summary

  • Additional Paid In Capital for the quarter ending June 29, 2020 was $-66.2 Million (a -1.05% decrease compared to previous quarter)
  • Year-over-year quarterly Additional Paid In Capital decreased by -34.11%
  • Annual Additional Paid In Capital for 2019 was $-78.9 Million (a -19.54% decrease from previous year)
  • Annual Additional Paid In Capital for 2018 was $-98 Million (a -4.31% decrease from previous year)
  • Annual Additional Paid In Capital for 2017 was $-102 Million (a -4.82% decrease from previous year)
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Additional Paid In Capital of PDL BioPharma, Inc.

Most recent Additional Paid In Capitalof PDLI including historical data for past 10 years.

Interactive Chart of Additional Paid In Capital of PDL BioPharma, Inc.

PDL BioPharma, Inc. Additional Paid In Capital for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $-66.16 $-66.87
2019 $-78.88 $-100.42 $-94.47 $-96.87 $-78.88
2018 $-98.03 $-97.64 $-100.23 $-101.49 $-98.03
2017 $-102.44 $-102.59 $-115.26 $-113.71 $-102.44
2016 $-107.63 $-119.47 $-116.54 $-117.21 $-107.63
2015 $-117.98 $-118.54 $-119.16 $-119.39 $-117.98
2014 $-119.87 $-120.18 $-120.59 $-121.01 $-119.87
2013 $-233.17 $-233.52 $-233.68 $-233.91 $-233.17
2012 $-234.07 $-234.37 $-234.56 $-234.79 $-234.07
2011 $-161.75 $-161.89 $-162.02 $-171.13 $-161.75
2010 $-87.37 $-90.32 $-195.98 $-87.37

Business Profile of PDL BioPharma, Inc.

Sector: Other
Industry: Other
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.